Accelerated innovation. Resources in the hands of health workers. Profit returned to the frontline.
Learn more about how we #BackTheFrontline by investing in innovators developing scalable solutions to COVID-19 from Johnson & Johnson Impact Ventures Chair Joe Wolk.
Follow along with us on @JNJGlobalHealth on Twitter and/or Instagram to hear from our leaders, employees and partners around the world about how YOU can meaningfully contribute.
by Christa Myers, Process Engineer, and Marc Pelletier, PhD, Process Specialist
Blog
During a global pandemic, the pharmaceutical industry must juggle the need for speed and the need to protect patient safety. A strong regulatory strategy makes it possible to accelerate drug development without getting slowed down by compliance considerations.
Funding supports efforts by National Organization for Rare Disorders (NORDⓇ) and Global Genes to address needs of the rare disease community arising from COVID-19 pandemic
Press Release
BOSTON, June 24, 2020 /3BL Media/ -- The Alexion Charitable Foundation, launched by Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in February 2020, has announced it has awarded a total of $1.1 million in initial grants that align with its Rare Belonging® focus. Rare Belonging seeks to advance emotional well-being and educational opportunities, and provide relief for critical needs, for those living with or affected by a rare disease.
Imagine spending years feeling isolated and alone as you navigate a long winding road to diagnosis, searching for answers. You finally hear the words “multiple sclerosis” (MS) and although shocking, you feel some sense of relief to have an answer. But as you search for stories of others who have walked this same path, the faces staring back at you are nothing like your own. Once again, you feel isolated and alone, this time with the shame of feeling different.
After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.
Along with the Society for Immunotherapy of Cancer we strive for a future #Immune2Cancer because to our team, cancer immunotherapy research is personal. Our scientists are researching potential, new cancer treatment options for our loved ones and yours.
Company is ranked No. 1 in industry on the 2020 100 Best Corporate Citizens list
Press Release
3BL Media has named Merck to its annual 100 Best Corporate Citizens ranking, recognizing outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest, U.S. public companies.
by Mark Paskanik, AIA, LEED AP BD+C, Senior Laboratory Planner
Article
Testing is a crucial component of our global response to COVID-19. The more people we can test for the virus, the better we can understand the threat we’re up against.
Producing enough tests and making them available to the public is just one half of this challenge. Processing the results quickly is the other.
by Michael Sneed, Chief Communication Officer, Johnson & Johnson
Blog
Tomorrow I will have the distinct honor of participating in a panel discussion held by the Congressional Black Caucus Foundation, titled Black America – The Double Pandemic, where I will join experts examining the incredibly damaging impact of the COVID-19 pandemic on the Black community.
